Teva Pharmaceutical Industries Limited Sponsored ADR Stock

$18.11

1.66% today

NYSE, Sep 16, 08:46 pm CET

ISIN

US8816242098

Symbol

TEVA

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Teva Pharmaceutical Industries Limited Sponsored ADR Stock price

$18.41

+10.47 131.86% 5Y

NYSE, Closing price Fri, Sep 13 2024

+0.40 2.22%

ISIN

US8816242098

Symbol

TEVA

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$20.86b
Enterprise Value	$37.73b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	18.19
EV/Sales (TTM) EV/Sales	2.31
P/S ratio (TTM) P/S ratio	1.28
P/B ratio (TTM) P/B ratio	3.28
Revenue growth (TTM) Revenue growth	8.38%
Revenue (TTM) Revenue	$16.30b
EBIT (operating result TTM) EBIT	$3.51b
Free Cash Flow (TTM) Free Cash Flow	$2.07b
Cash position	$2.26b
EPS (TTM) EPS	$-0.39
P/E forward	21.57
P/S forward	1.28
EV/Sales forward	2.32
Short interest	2.13%

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Get Started for Free Today

Teva Pharmaceutical Industries Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

8x Buy

73%

3x Hold

27%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

Buy

73%

Hold

27%

Analyst Estimates with Stock Price Targets

Financial data from Teva Pharmaceutical Industries Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Net Profit	-443 -443	80% 80% -3%
Depreciation and Amortization	1,080 1,080	12% 12% 7%
Stock Compensation	119 119	3% 3% 1%
Operating Cash Flow	2,563 2,563	13% 13% 16%
Investments	489 489	6% 6% 3%
Dividend Paid	- -	- -
Free Cash Flow	2,074 2,074	14% 14% 13%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Teva Pharmaceutical Industries Limited Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

5 days ago

Teva to Present at the Bank of America 2024 Global Healthcare Conference

TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Bank of America 2024 Global Healthcare Conference on Thursday, September 19, 2024. The presentation will begin at 8.15 A.M. British summer time (3.15 A.M. Eastern Time).

Positive

Reuters

●

6 days ago

Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial

Baltimore said on Tuesday that it has settled with Walgreens over claims that the pharmacy operator fueled opioid addiction in the Maryland city, the latest in a series of settlements totaling $402.5 million ahead of a trial scheduled to begin next week.

Negative

Reuters

●

6 days ago

Exclusive: Teva faces EU fine for disparaging rival multiple sclerosis medicine, sources say

Teva , the world's largest generic drugmaker, will be hit with an EU antitrust fine in the coming weeks for disparaging a rival product to its blockbuster multiple sclerosis medicine Copaxone, people with direct knowledge of the matter said on Tuesday.

More Teva Pharmaceutical Industries Limited Sponsored ADR News

Company Profile

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Head office	Israel
CEO	Richard Francis
Employees	37,226
Founded	1901
Website	www.tevapharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now